Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

MRNA.NASDAQ

Moderna

Healthcare | Biotechnology

Biotechnology company pioneering messenger RNA therapeutics and vaccines, gained prominence with COVID-19 vaccine development.

Flagship Insight

Why the Market Misprices This Programmable Biology Platform Beyond Pandemic Windfalls

There is sharp divergence across reports regarding this asset's near-term commercial execution, yet high consensus exists on its long-term oncology platform potential. While persistent cash burn and hostile regulatory shifts act as primary frictions, the clinical validation of personalized cancer vaccines remains the ultimate structural driver.

Forecast TimelineUpdated On Jul 02 2026

Moderna (MRNA) Stock Forecast and AI Rating

Recommendation

No Action - Keep Monitoring

Only one horizon is positive; wait for broader confirmation.

2027

1-Year

NEUTRAL

$82

+2.2%

+33% IF INCL. DIVS

2029

3-Year

N/A

$126

+111%

2031

5-Year

BUY

$171

+114%

+186% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The base-case narrative centers on a structural transition from a pandemic-era respiratory vaccine vendor to a high-margin, programmable oncology platform. While near-term performance is weighed down by the post-pandemic revenue cliff and a restrictive high-rate macro regime, the company's deep liquidity reserves provide a multi-year runway to fund late-stage clinical trials. The core investment thesis rests on the non-linear valuation inflection expected as personalized cancer vaccines and latent virus pipelines achieve commercialization.

Key insights

The primary long-term driver is the clinical validation of the individualized neoantigen therapy platform in oncology.
Near-term headwinds include intense commercial competition in the seasonal respiratory market and regulatory pricing pressures.
A robust cash buffer of over seven billion dollars insulates the asset from immediate debt refinancing risks.
Major risks include potential Phase 3 clinical failures and accelerated cash depletion before the projected cash-flow breakeven.
Sophisticated investors should monitor the upcoming regulatory decisions and clinical readouts to confirm platform scalability.
Disagreements persist regarding the commercial viability of the respiratory franchise and the timeline to achieve profitability.
Practical implications suggest accumulating shares during near-term margin-trough pessimism to capture long-term platform optionality.
The integration of artificial intelligence in drug design structurally reduces research and development failure rates.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Moderna quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Moderna.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$67.80	$76.04	$89.33	$736.09
Quarter 2+6M	Jan 02, 2027	$61.02	$74.13	$85.76	$724.14
Quarter 3+9M	Apr 02, 2027	$56.14	$75.25	$92.62	$713.57
Quarter 4+1Y	Jul 02, 2027	$50.52	$79.33	$97.25	$723.38
Quarter 5+15M	Oct 02, 2027	$48.00	$81.51	$109.62	$716.61
Quarter 6+18M	Jan 02, 2028	$45.12	$85.50	$120.58	$738.34
Quarter 7+21M	Apr 02, 2028	$44.43	$91.71	$142.28	$746.91
Quarter 8+2Y	Jul 02, 2028	$46.65	$96.25	$153.67	$771.93
Quarter 9+27M	Oct 02, 2028	$51.32	$103.07	$192.08	$782.73
Quarter 10+30M	Jan 02, 2029	$48.75	$109.90	$201.69	$807.31
Quarter 11+33M	Apr 02, 2029	$51.67	$116.22	$213.79	$822.72
Quarter 12+3Y	Jul 02, 2029	$49.61	$120.81	$224.48	$846.10
Quarter 13+39M	Oct 02, 2029	$54.37	$125.79	$233.46	$852.53
Quarter 14+42M	Jan 02, 2030	$51.11	$133.36	$247.47	$882.91
Quarter 15+45M	Apr 02, 2030	$48.56	$140.39	$259.84	$900.46
Quarter 16+4Y	Jul 02, 2030	$50.50	$144.83	$272.83	$922.67
Quarter 17+51M	Oct 02, 2030	$48.01	$149.54	$283.74	$935.91
Quarter 18+54M	Jan 02, 2031	$46.09	$157.26	$303.52	$952.30
Quarter 19+57M	Apr 02, 2031	$45.17	$164.09	$318.70	$976.28
Quarter 20+5Y	Jul 02, 2031	$43.81	$170.69	$334.63	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's misclassification of the asset as a traditional, cyclical vaccine manufacturer rather than a programmable biological software platform. While the crowd fixates on near-term cash burn and trailing respiratory sales, they fail to recognize that the underlying mRNA technology operates as an operating system where success in one clinical area mathematically derisks others. Furthermore, the market is misinterpreting recent litigation settlements and cost-cutting measures; these actions actually remove major intellectual property overhangs and secure the necessary cash runway to reach profitability. By treating research and development as a wasting expense rather than a capital investment in oncology and latent virus pipelines, the crowd is severely underestimating the non-linear valuation inflection that will occur once personalized cancer therapies are validated.

Advisor Disagreement

The primary disagreement across reports centers on the commercial viability of the respiratory vaccine franchise and the realistic timeline to achieve cash-flow breakeven. Optimistic perspectives assume that combination vaccines will easily establish a stable revenue floor, while cautious views argue that intense competition from entrenched incumbents will lead to market share losses and margin compression. Additionally, there is divergence regarding the valuation multiple applied to the pre-profit pipeline, with some treating the platform as a high-growth technology play and others evaluating it strictly on near-term cash burn and book value.

Financial Reviews by iPulse AI

Earnings and financials

The company's recent financial performance shows a sharp drop in revenues from pandemic-era peaks, leading to large operating losses and negative cash flow. However, a closer look reveals that recent massive losses were heavily driven by one-time legal settlements rather than ongoing operational failures. While the current financial picture looks challenging, there is general agreement that the company is actively cutting costs and restructuring its business to narrow these losses. Opinions differ on how quickly the company can recover, with some expecting a steady return to profitability by late 2028 as new products launch, while others remain highly skeptical about the near-term sales potential of the new respiratory vaccines. Overall, the financial trend is in a transition phase, requiring investors to look past current losses toward the long-term potential of the pipeline.

Profitability and margins

Profit margins have collapsed from their highly profitable pandemic levels, with operating margins currently deep in negative territory due to high fixed costs and lower revenues. This margin pressure is a structural challenge of transitioning from a single-product monopoly to a diversified commercial business. Consensus exists that margins will remain negative in the near term as the company continues to invest heavily in its pipeline. However, the outlook for future profitability is a major point of disagreement. Optimistic views expect a dramatic margin expansion once high-priced, personalized cancer therapies are approved and scaled, leveraging the company's existing manufacturing capacity. Conversely, cautious perspectives argue that intense competition in the respiratory market and government pricing controls will permanently limit margin potential, keeping profitability out of reach for longer than management projects.

Balance sheet and leverage

The company's balance sheet is its strongest defense, featuring a massive cash reserve of over seven billion dollars and almost no debt. This financial fortress provides excellent protection against high interest rates and tight credit markets, ensuring the company does not face immediate refinancing risks. There is high consensus that this deep liquidity gives the company a vital multi-year runway to fund its expensive clinical trials without needing to borrow money or issue dilutive new shares. However, opinions diverge on how quickly this cash pile will be consumed. Cautious assessments emphasize that the high annual burn rate makes this runway finite, meaning any delays in product approvals could eventually force a difficult capital raise, while supportive views believe the cash is more than sufficient to bridge the gap to profitability.

Capex and investment intensity

The company's heavy spending is currently focused on research and development rather than building physical factories, as much of its manufacturing infrastructure is already complete. This high investment intensity is a deliberate strategy to validate its technology platform across cancer treatments and rare diseases. While this massive spending puts significant pressure on near-term cash flow, it is building a strong intellectual property moat that could lower future drug discovery costs. There is a clear consensus that this spending is necessary to transition away from pandemic-related products, but analysts disagree on the efficiency of this capital allocation. Cautious views warn of the risk of overinvesting in unproven areas, while optimistic perspectives see this intense spending as a crucial step to securing a dominant position in the future of medicine.